U.S. Markets closed
  • S&P 500

    3,669.01
    +6.56 (+0.18%)
     
  • Dow 30

    29,883.79
    +59.87 (+0.20%)
     
  • Nasdaq

    12,349.37
    -5.74 (-0.05%)
     
  • Russell 2000

    1,838.03
    +1.98 (+0.11%)
     
  • Crude Oil

    44.78
    -0.50 (-1.10%)
     
  • Gold

    1,833.30
    +3.10 (+0.17%)
     
  • Silver

    24.19
    +0.11 (+0.46%)
     
  • EUR/USD

    1.2115
    +0.0037 (+0.3029%)
     
  • 10-Yr Bond

    0.9480
    +0.0140 (+1.50%)
     
  • Vix

    21.17
    +0.40 (+1.93%)
     
  • GBP/USD

    1.3371
    -0.0052 (-0.3891%)
     
  • USD/JPY

    104.4860
    +0.1700 (+0.1630%)
     
  • BTC-USD

    19,170.09
    +176.18 (+0.93%)
     
  • CMC Crypto 200

    376.17
    +11.25 (+3.08%)
     
  • FTSE 100

    6,463.39
    +78.66 (+1.23%)
     
  • Nikkei 225

    26,800.98
    +13.44 (+0.05%)
     

Radius Health to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 5, 2019

WALTHAM, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Radius Health (RDUS) announced today that it will release its third quarter 2019 financial results on Tuesday, November 5, 2019. The Company will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the results and provide a company update.

Conference Call Information:
Date: Tuesday, November 5, 2019
Time: 4:30 p.m. ET
Domestic Dial-In Number: (866) 323-7965
International Dial-In Number: (346) 406-0961
Conference ID: 2490257

A replay of the conference call/webcast will be available from Tuesday, November 5 at 6:30 p.m. ET and will be archived on the Company's website for 90 days. To access the replay, dial (855) 859-2056 U.S. or (404) 537-3406 for International, using conference ID number 2490257.

The live audio webcast of the call can be accessed from the Investors section of the Company’s website, https://ir.radiuspharm.com/events-and-presentations. The full text of the announcement and financial results will also be available on the Company’s website.

About Radius

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. For more information, please visit www.radiuspharm.com.

Investor & Media Relations Contact:

Elhan Webb, CFA
Email: ewebb@radiuspharm.com
Phone: 617-551-4011